Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: a potential novel prognostic marker for breast cancer

Youssef, G., Gillett, C., Agbaje, O., Crompton, T. and Montano Hernandez, X. 2014. Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: a potential novel prognostic marker for breast cancer. Modern Pathology. 27, pp. 361-374. doi:10.1038/modpathol.2013.129

TitlePhosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: a potential novel prognostic marker for breast cancer
TypeJournal article
AuthorsYoussef, G.
Gillett, C.
Agbaje, O.
Crompton, T.
Montano Hernandez, X.
Abstract

We have identified a ligand-independent mechanism whereby the tumor suppressor, TP53, induces nerve growth factor receptor, NTRK1, phosphorylation at Y674/Y675 (NTRK1-pY674/pY675), via the repression of the NTRK1-phosphatase, PTPN6. This results in suppression of breast cancer cell proliferation. In this investigation, we aimed to establish whether perturbation of the wild-type TP53-NTRK1-pY674/pY675-PTPN6 pathway has an impact on disease-free survival of breast cancer patients without neo-adjuvant treatment. A total of 308 tumor samples were stained for NTRK1, NTRK1-pY674/pY675, PTPN6, and TP53 expression. Association between expression levels and disease-free survival was determined by the univariate/multivariate and Kaplan-Meir methods of analysis. DNA from tumors was sequenced to identify mutant or wild-type TP53. Tumors expressing NTRK1-pY674/pY675 but with undetectable or low levels of PTPN6 and TP53 were associated with prolonged 5, 10, and 15 years' disease-free survival by 48%, 36%, and 37%, respectively, in the multivariate analysis (P<0.05). A similar result was observed in tumors expressing wild-type TP53, NTRK1-pY674/pY675, and low or undetectable levels of PTPN6. Given that estrogen receptor-positive breast cancers encode wild-type TP53, we analyzed this expression pattern in these tumors. Multivariate analysis showed that it was significantly and independently predictive of prolonged survival by 66%, 70%, and 84%, respectively, (P<0.05). The Kaplan-Meir method demonstrated that NTRK1-pY674/pY675 together with undetectable or low levels of PTPN6 correlated with 59% probability of disease-free survival (median survival 15 years), compared with 7% probability of disease-free survival (median survival 4.5 years) when absent. In luminal A tumors, the presence of this pattern was estimated to have a 61% probability of disease-free survival (median survival 15 years), compared with 6% probability of disease-free survival (median survival 3 years) when it was absent. These results strongly suggest that expression of NTRK1-pY674/pY675 together with wild-type TP53 and low levels of PTPN6 expression are predictors of improved disease-free survival and that they could be useful biomarkers to predict clinical outcome.

KeywordsNTRK1, TP53, PTPN6 and Breast Cancer
Article number23948750
JournalModern Pathology
Journal citation27, pp. 361-374
ISSN0893-3952
Year2014
PublisherNature Publishing Group
Digital Object Identifier (DOI)doi:10.1038/modpathol.2013.129
PubMed ID23948750
Web address (URL)https://www.ncbi.nlm.nih.gov/pubmed/23948750
Publication dates
Published online16 Aug 2013
Published in printMar 2014

Related outputs

The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma
Youssef, G., Gillett, C., Rampling, D., Chagtai, T., Virasami, A., Barton, J., Edwards, D., Sebire, N., Anderson, J. and Montano, X. 2019. The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma. Human Pathology. 86, pp. 182-192. doi:10.1016/j.humpath.2018.12.003

A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma
Dvorkina, M., Nieddu, V., Chakelam, S., Pezzolo, A., Cantilena, S., Leite, A.P., Chayka, O., Regad, T., Pistorio, A., Sementa, A.R., Virasami, A., Barton, A., Montano, X., Lechertier, T., Brindle, N., Morgenstern, D., Lebras, M., Burns, A.J., Saunders N.J., Hodivala-Dilke, K., Bagella, L., De The, H., Anderson, J., Sebire, N., Pistoia, V., Sala, A. and Salomoni, P. 2016. A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma. Clinical Cancer Research. 22 (13), pp. 3398-3409. doi:10.1158/1078-0432.CCR-15-2081

Permalink - https://westminsterresearch.westminster.ac.uk/item/qwy4x/phosphorylation-of-ntrk1-at-y674-y675-induced-by-tp53-dependent-repression-of-ptpn6-expression-a-potential-novel-prognostic-marker-for-breast-cancer


Share this
Tweet
Email

Usage statistics

8 total views
0 total downloads
1 views this month
0 downloads this month
These values are for the period from September 2nd 2018, when this repository was created

Export as